Literature DB >> 618989

Heterogeneity of human factor VIII. I. Characterization of factor VIII present in the supernatant of cryoprecipitate.

J Over, B N Bouma, J A van Mourik, J J Sixma, R Vlooswijk, I Bakker-Woudenberg.   

Abstract

Recent observations suggest that plasma F VIII consists of a series of molecules with different molecular weights. The data described in this paper suggest that sup F VIII represents the molecules with relatively low molecular weights whereas the molecules with the highest molecular weights appear in cryo F VIII. Sup F VIII was associated with VIII:C and VIIIR:Ag, but ristocetin cofactor activity was lacking. Although the immunoprecipitation characteristics of sup F VIII with rabbit antifactor VIII were different from those of cryo F VIII, immunological identity was observed in immunodiffusion and crossed immunoelectrophoresis. In 0.8M NaCl sup F VIII dissociated into VIIIR:Ag of relatively high molecular weight and VIII:C of low molecular weight. No indications were obtained that the presence of sup F VIII was the result of proteolytic degradation of factor VIII. VIII:C of sup F VIII was more labile in vitro than VIII:C in plasma. It could be activated by traces of thrombin in a way similar to plasma F VIII. In patients with classic von Willebrand's disease relatively more VIII:C remained in the supernatant after cryoprecipitation of plasma.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 618989

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  6 in total

1.  Studies on the procurement of blood coagulation factor VIII: effects of plasma freezing rate and storage conditions on cryoprecipitate quality.

Authors:  A Farrugia; C Prowse
Journal:  J Clin Pathol       Date:  1985-04       Impact factor: 3.411

2.  Permanent cell line expressing human factor VIII-related antigen established by hybridization.

Authors:  C J Edgell; C C McDonald; J B Graham
Journal:  Proc Natl Acad Sci U S A       Date:  1983-06       Impact factor: 11.205

3.  Carbohydrate of the factor VIII/von Willebrand factor in von Willebrand's disease.

Authors:  T S Zimmerman; R Voss; T S Edgington
Journal:  J Clin Invest       Date:  1979-11       Impact factor: 14.808

4.  Survival of 125iodine-labeled Factor VIII in normals and patients with classic hemophilia. Observations on the heterogeneity of human Factor VIII.

Authors:  J Over; J J Sixma; M H Bruïne; M C Trieschnigg; R A Vlooswijk; N H Beeser-Visser; B N Bouma
Journal:  J Clin Invest       Date:  1978-08       Impact factor: 14.808

5.  Functional domains on von Willebrand factor. Recognition of discrete tryptic fragments by monoclonal antibodies that inhibit interaction of von Willebrand factor with platelets and with collagen.

Authors:  J J Sixma; K S Sakariassen; H V Stel; W P Houdijk; D W In der Maur; R J Hamer; P G de Groot; J A van Mourik
Journal:  J Clin Invest       Date:  1984-09       Impact factor: 14.808

6.  Botrocetin (venom coagglutinin): reaction with a broad spectrum of multimeric forms of factor VIII macromolecular complex.

Authors:  K M Brinkhous; M S Read; W A Fricke; R H Wagner
Journal:  Proc Natl Acad Sci U S A       Date:  1983-03       Impact factor: 11.205

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.